Active	Status	Sponsor type	Region	Phase	Filter
24 Active 9 Inactive 33 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Renzo, Nicola Di
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML	Recruiting	2	98	Europe	RVU120, SEL120, Venetoclax	Ryvu Therapeutics SA	Acute Myeloid Leukemia	02/26	09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML	Recruiting	2	94	Europe, Canada	RVU120, SEL120	Ryvu Therapeutics SA	Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome	02/26	09/26
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients	Recruiting	1/2	122	Europe	Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Relapsed or Refractory Hodgkin's Lymphoma	04/27	04/30
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -	Recruiting	N/A	190	Europe	acalabrutinib, Calquence	AstraZeneca, Yghea	Chronic Lymphocytic Leukemia	02/30	02/30